Table 3.

This shows the sensitivity and specificity of PET/CT versus non-contrast CT in monitoring for recurrence 1 year after lobectomy for clinical stage 1 NSCLC. Table 3A shows the sensitivity of PET/CT and non-contrast CT for all patients included in this study. For all patients included in this study, PET/CT is more sensitive than non-contrast CT alone in monitoring for recurrence 1 year after lobectomy.Table 3B compares the sensitivity of PET/CT and non-contrast CT for the subset of patients confirmed to have stage 1 NSCLC after surgery. For these patients, there was no difference in the sensitivity of PET/CT and non-contrast CT in monitoring for recurrence. Table 3C shows the sensitivity and specificity of PET/CT and non-contrast CT monitoring for recurrence in the subset of patients upstaged to stage 2 or 3 after surgery. PET/CT is more sensitive than non-contrast CT in monitoring for recurrence in this subset of patients. There was no statistically significant difference in the specificity of PET/CT and non-contrast CT in all subsets of patients.

A. All pathologic stages, clinical stage 1
	CT	PET/CT	CT Relative to PET/CT
Sensitivity (%)	56.3	100	56.3 (p = 0.016, 95% CI: 37-87)
Specificity (%)	96	93.2	103 (p = 0.62, 95% CI: 22-165)
B. Pathologic Stage 1
	CT	PET/CT	CT Relative to PET/CT
Sensitivity (%)	83.3	100	83.3 (p = 0.31, 95% CI: 52-124)
Specificity (%)	95.2	93.7	102 (p = 0.56, 95% CI: 15.7-188)
C. Pathologic Stage 2/3
	CT	PET/CT	CT Relative to PET/CT
Sensitivity (%)	40	100	40 (p = 0.03, 95% CI: 18.7-85.4)
Specificity (%)	100	90.9	110 (p = 0.31, 95% CI: 58.8-285)